tesamorelin nash: Frequently asked questions

Dosing gaps longer than 3 consecutive days reset the metabolic cascade. IGF-1 drops to baseline within 72 hours. Restart dosing immediately, but expect a 2–3 week delay before hepatic fat reduction resumes.

Fibrosis reversal is the slowest endpoint. Some trials show continued improvement through month 18–24 even when month 12 biopsies show minimal change. If hepatic fat reduced appropriately but fibrosis persists, extend the observation window to 18 months before concluding non-response.

IGF-1 levels decline to baseline within 5–7 days of stopping tesamorelin, and visceral fat mobilization halts correspondingly. Missing 2–3 consecutive doses won't reverse prior hepatic fat reduction immediately, but missing a full week begins measurable rebound. Resume dosing at the standard 2mg daily without attempting to

Check adherence first, then verify reconstitution and storage protocols. Degraded peptide delivers no therapeutic effect. If both are confirmed correct, measure IGF-1 levels: non-responders typically show <30% IGF-1 increase from baseline, suggesting pituitary hyporesponsiveness or GH resistance. In clinical trials, 10–15% of participants showed minimal hepatic fat reduction (<10%) despite appropriate IGF-1 elevation, likely due to genetic variation in adipocyte GH receptor density or alternative metabolic pathways driving steatosis. These patients may benefit more from combination approaches targeting insulin resistance or de novo lipogenesis.

Supraphysiological IGF-1 increases risk of insulin resistance paradoxically. Reduce dose to 1.5mg or implement alternate-day dosing to bring IGF-1 into the therapeutic range (200–350 ng/mL). Monitor fasting glucose and HbA1c monthly during dose adjustment.

Check IGF-1 levels first. Non-responders typically show IGF-1 elevation below 50 ng/mL from baseline. If IGF-1 is adequate but fat reduction stalls, the issue is likely dietary: tesamorelin mobilizes stored fat, but caloric surplus will replace it faster than oxidation clears it.

Monitor HbA1c and fasting glucose every 4 weeks during the first 12 weeks of treatment. Transient glucose elevations of 3–8 mg/dL are common in the first month due to GH's counter-regulatory effects on insulin signaling, but these typically stabilize as visceral fat reduction improves peripheral insulin sensitivity. If fasting glucose rises above 110 mg/dL or HbA1c increases by >0.5%, consider metformin co-administration to offset insulin resistance. Clinical trials have used this combination successfully without compromising tesamorelin's hepatic fat reduction. Discontinuation is warranted only if glucose control worsens despite metformin or if HbA1c exceeds 9%.

Arthralgia occurs in 10–12% of tesamorelin users and typically presents as morning stiffness in hands, knees, or shoulders within 4–8 weeks of starting treatment. The mechanism is GH-mediated fluid retention in periarticular tissues rather than inflammatory arthritis. Standard management includes continuing treatment while symptoms are mild to moderate (most cases resolve spontaneously by week 12), using low-dose NSAIDs if needed, and monitoring for progression. If pain becomes severe or persists beyond 16 weeks, dose reduction to 1mg daily often maintains hepatic benefit while eliminating joint symptoms.